COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every two weeks

Methods

Variants of concern

RCTs

Vaccine types

Access all forest plots

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04495933
The University of Queensland; Syneos Health; CSIRO Manufacturing; Seqirus; Coalition for Epidemic Preparedness Innovations
Chappell K, Lancet, 2021

Full text
Commentary
Protein subunit

SARS-CoV-2 Sclamp 5-mcg D

SARS-CoV-2 Sclamp 15-mcg

SARS-CoV-2 Sclamp 45-mcg

SARS-CoV-2 Sclamp 45-mcg

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 at one center in Australia. N=120
Some concerns
Details

Full description

NCT04611802
Novavax
Dunkle L M, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Healthy adults in 113 sites in the USA and 6 in Mexico N=29949
Some concerns
Details

Full description

NCT04368988
Novavax
Formica N, PLoS Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

NVX-CoV2373 5mcg D0

25mcg NVX-CoV2373 D0/D21

25mcg NVX-CoV2373 D0

Placebo

RCT
Phase 2
Healthy adults (stable comorbidities permitted) aged 18-84 years at 17 centers in Australia and USA N=1288
Some concerns
Details

Full description

NCT04537208
Sanofi Pasteur, GlaxoSmithKline
Goepfert P, Lancet, 2021

Full text
Commentary
Protein subunit

CoV2 preS dTM LD + AFO3

CoV2 preS dTM LD + ASO3

CoV2 preS dTM HD + AFO3

CoV2 preS dTM HD + ASO3

CoV2 preS dTM HD

Placebo

RCT
Phase 1-2
Health adults aged 18 years and older and SARS-CoV-2 infection-free in 10 centres in the USA. N=271
Some concerns
Details

Full description

NCT04583995; EudraCT 2020-004123-16
Novavax
Heath P, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. N=15187
Some concerns
Details

Full description

NCT04695652
Medigen Vaccine Biologics+Dynavax+NIAID
Hsieh SM, Lancet, 2021

Full text
Commentary
Protein subunit

MVC-COV1901

Placebo

RCT
Phase 2
Healthy adults and adults with stable pre-existing medical conditions at 11 centers in Taiwan. N=3854
Some concerns
Details

Full description

NCT04368988
Novavax
Keech C, N Engl J Med, 2020

Full text
Commentary
Protein subunit

25mcg NVX-D0/21

NVX-CoV2373

25mcg NVX/M1-D0/21

25mcg NVX/M1+Placebo-D0/2

Placebo

RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

ChiCTR2100045108
Guangdong Provincial Center for Disease Control and Prevention
Liao Y, Emerg Microbes Infec, 2021

Full text
Commentary
Protein subunit

V-01 10 mcg

V-01 25 mcg

V-01 50 mcg

Placebo

RCT
Phase 1
Healthy seronegative adults with no history of COVID-19 in a single center in China N=180
Some concerns
Details

Full description

NCT04640402
West China Hospital of Sichuan University
Meng F, Signal Transduct Tar, 2021

Full text
Commentary
Protein subunit

COVID-19 vaccine (Sf9 cel

COVID-19 vaccine (Sf9 cel

COVID-19 vaccine (Sf9 cel

COVID-19 vaccine (Sf9 cel

Placebo

RCT
Phase 2
Healthy adults with no history of COVID-19 in a single centre in China N=960
Some concerns
Details

Full description

NCT04530656
West China Hospital of Sichuan University
Meng F, Signal Transduct Tar, 2021

Full text
Commentary
Protein subunit

Sf9 cells vaccine

Sf9 cells vaccine

Sf9 cells vaccine

Placebo

RCT
Phase 1
Healthy adults with no history of COVID-19 in a single centre in China N=168
Some concerns
Details

Full description

NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, SSRN, 2021

Full text
Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

Placebo

RCT
Phase 2
Healthy HIV-negative and seronegative adults at 2 centers in Vietnam N=560
Some concerns
Details

Full description

NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, SSRN, 2021

Full text
Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

RCT
Phase 1
Healthy HIV-negative and seronegative adults at a single center in Vietnam N=60
Some concerns
Details

Full description

RPCEC00000338
Finlay Vaccine Institute
Pérez-Rodríguez S, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

FINLAY-FR-1A 25 mcg

FINLAY-FR-1A 50 mcg

FINLAY-FR-1

RCT
Phase 1
Adults, age 19-59, with no history of previous SARS-CoV-2 infection at a single center in Cuba. N=60
Low
Details

Full description

NCT04405908
Clover Biopharmaceuticals, Chengdu, China
Richmond P, Lancet, 2021

Full text
Commentary
Protein subunit

SCB-2019 3 mcg

SCB-2019 3 mcg + AS03

SCB-2019 3 mcg + CpG/Alum

SCB-2019 9 mcg

SCB-2019 9 mcg + AS03

SCB-2019 9 mcg + CpG/Alum

SCB-2019 30 mcg

SCB-2019 30 mcg + AS03

SCB-2019 30 mcg + CpG/Alu

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults aged 18-75 years at one study center in Australia N=151
Low
Details

Full description

NCT04527575
EpiVac LLC; VECTOR
Ryzhikov AB, Infektsiia Immun, 2021

Full text
Commentary
Protein subunit

EpiVacCorona

Placebo

RCT
Phase 2
Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia. N=86
Some concerns
Details

Full description

NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 2
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406
Some concerns
Details

Full description

ChiCTR2100045107
Institute of Biophysics, Chinese Academy of Sciences; Livzon Bio Inc.; Guangdong Provincial Centre for Disease Control and Prevention; Gaozhou Center for Disease Control and Prevention
Shu Y-J, Chin. Med. J., 2021

Full text
Commentary
Protein subunit

V-01 10 mcg

V-01 25 mcg

V-01 50 mcg

Placebo

RCT
Phase 2
Younger (18-59) and older (60+) healthy adults with no current or past SARS-CoV-2 infection (PCR and ELISA) at a single centre in China N=880
Some concerns
Details

Full description

NCT04762680
Sanofi Pasteur + GlaxoSmithKline
Sridhar S, medrxiv, 2021

Full text
Commentary
Commentary
Protein subunit

CoV2 preS dTM 15µg

CoV2 preS dTM 10µg

CoV2 preS dTM 5µg

RCT
Phase 2
Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras N=722
Low
Details

Full description

RPCEC00000354
Instituto Finlay de Vacunas
Toledo-Romani ME, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

FINLAY-FR-2

FINLAY-FR-2-/boost FR-1

Placebo

FINLAY-FR-2

RCT
Phase 3
Adults in medically stable condition with no self-reported previous COVID-19 infection at 48 centers in Cuba N=44031
Some concerns
Details

Full description

NCT04466085
Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Yang S, Lancet, 2021

Full text
Commentary
Protein subunit

ZF2001 25 mcg 2 doses

ZF2001 50 mcg 2 doses

ZF2001 25 mcg 3 doses

ZF2001 50 mcg 3 doses

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 infection-free adults aged 18-59 at 1 center in China N=900
Low
Details

Full description

NCT04445194
Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Yang S, Lancet, 2021

Full text
Commentary
Protein subunit

ZF2001 25 mcg 3 doses

ZF2001 50 mcg 3 doses

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-59 at 2 centers in China N=50
Some concerns
Details

Full description